StockData
OKYO Pharma Ltd logo

OKYO Pharma Ltd (OKYO) shareholders

OKYONasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 20, 2026Score 1/30
$1.17−0.18 (-13.33%)

Close on Nov 16, 2026Market cap $61.40MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
12.4%
6M of 52M shares
Institutional holders
19
8 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $136.04K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Point72 Asset Management, L.P.
Joint filing with Point72 Capital Advisors, Inc. (7.90%), Steven A. Cohen (7.90%)
4,058,4457.90%13G (passive)Feb 17, 2026
Alex Silverstein
Joint filing with Sirenia Capital Management LP (7.70%)
4,054,0547.70%13G (passive)Mar 31, 2026
Chernett Jorey3,802,1949.50%13G (passive) amendmentDec 31, 2025
Woodline Partners LP3,652,1907.00%13G (passive)Mar 31, 2026
Laura Natalia Monica Fonda1,928,4515.01%13G (passive)Jul 22, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of OKYOValueChange% of portfolio
Woodline Partners LP3,652,7686.96%$5.48M+5780.02%
Stonepine Capital Management, LLC862,9961.64%$1.29M+12,9960.73%
Maven Securities LTD809,3171.54%$1.21M−366,2180.02%
Balyasny Asset Management L.P.580,5961.11%$870.89K−4,2000.00%
Opaleye Management Inc.375,2040.71%$562.81KNew0.05%
UBS Group AG55,0090.10%$82.51K−4,7510.00%
XTX Topco Ltd37,7690.07%$56.65K+1170.00%
Choreo, LLC33,2550.06%$49.88KNew0.00%
Quantinno Capital Management LP33,2550.06%$49.88KNew0.00%
Cerity Partners LLC12,8120.02%$19.22K–0.00%
Geode Capital Management, LLC12,0900.02%$18.14K–0.00%
Renaissance Technologies LLC11,2000.02%$16.80KNew0.00%
Jane Street Group, LLC10,3020.02%$15.45KNew0.00%
Steward Partners Investment Advisory, LLC6,0000.01%$9.00KNew0.00%
EFG International AG9230.00%$1.39K–0.00%
Osaic Holdings, Inc.1520.00%$228–0.00%
Continuum Advisory, LLC500.00%$75New0.00%
Morgan Stanley100.00%$15–0.00%
Caitong International Asset Management Co., Ltd30.00%$4New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026196M12.4%8 / 33 / 10M0M
Q1 2026126M12.2%4 / 21 / 26M1M
Q4 2025101M1.3%4 / 11 / 20M2M
Q3 202583M4.9%4 / 01 / 10M0M
Q2 202553M5.3%2 / 10 / 41M0M
Q1 202572M4.0%2 / 11 / 22M1M
Q4 202471M2.0%1 / 20 / 00M0M
Q3 202461M1.9%1 / 01 / 20M0M
Q2 202471M1.9%1 / 12 / 00M0M
Q1 202461M1.7%1 / 21 / 20M0M
Q4 202371M1.7%2 / 21 / 21M0M
Q3 202370M0.2%6 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Robert John DempseyCHIEF EXECUTIVE OFFICER, Director15,0000.03%Aug 7, 2026
Gary S. JacobCHIEF DEVELOPMENT OFFICER, Director112,4200.21%Aug 7, 2026
Rajkumar V. PatilChief Scientific Officer20,0300.04%Aug 7, 2026
Flavio MantelliCHIEF MEDICAL OFFICER20,0000.04%Aug 7, 2026
Keeren Rameshchandra ShahChief Financial Officer16,6670.03%Jun 10, 2026
Gabriele M. CerroneDirector, 10% owner21,400,33240.78%Aug 7, 2026
John P. BrancaccioDirector35,2010.07%Aug 7, 2026
Bernard DenoyerDirector––Jun 10, 2026
Willy Jules SimonDirector15,3830.03%Jun 10, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Rajkumar V. Patil
Chief Scientific Officer
Jul 27, 2026Buy+3,363$1.49$5.01K20,030
Rajkumar V. Patil
Chief Scientific Officer
Jul 27, 2026Award+3,363$1.49$5.01K20,030
Robert John Dempsey
CHIEF EXECUTIVE OFFICER, Director
Jul 22, 2026Buy+15,000$1.54$23.10K15,000
Robert John Dempsey
CHIEF EXECUTIVE OFFICER, Director
Jul 22, 2026Award+15,000$1.54$23.10K15,000
Flavio Mantelli
CHIEF MEDICAL OFFICER
Jul 21, 2026Buy+20,000$1.40$28.00K20,000
John P. Brancaccio
Director
Jul 21, 2026Buy+5,000$1.48$7.40K35,201
Gary S. Jacob
CHIEF DEVELOPMENT OFFICER, Director
Jul 21, 2026Buy+3,500$1.40$4.90K112,420
Gabriele M. Cerrone
Director, 10% owner
Jul 21, 2026Buy+22,500$1.45$32.63K10,873,916
Gabriele M. Cerrone
Director, 10% owner
Jul 21, 2026Award+22,500$1.45$32.63K10,873,916
Gary S. Jacob
CHIEF DEVELOPMENT OFFICER, Director
Jul 21, 2026Award+3,500$1.40$4.90K112,420
John P. Brancaccio
Director
Jul 21, 2026Award+5,000$1.48$7.40K35,201
Flavio Mantelli
CHIEF MEDICAL OFFICER
Jul 21, 2026Award+20,000$1.40$28.00K20,000
Gabriele M. Cerrone
Director, 10% owner
Jul 20, 2026Buy+25,000$1.40$35.00K10,851,416
Gabriele M. Cerrone
Director, 10% owner
Jul 20, 2026Award+25,000$1.40$35.00K10,851,416
Gabriele M. Cerrone
Director, 10% owner
Jun 8, 2026Award+300,000$1.72$516.00K10,826,416
Gabriele M. Cerrone
Executive Chairman, Director
Oct 27, 2023Other+70,071$1.50$105.11K9,177,903
Gabriele M. Cerrone
Executive Chairman, Director
Oct 23, 2023Other+499,468$1.50$749.20K9,107,832
John P. Brancaccio
Director
Sep 15, 2023Buy+16,670$1.50$25.01K16,670
Gabriele M. Cerrone
Executive Chairman, Director
May 19, 2022Buy+5,800,000$0.08$464.00K548,981,215
Gabriele M. Cerrone
Non-Executive Chairman, Director, 10% owner
May 19, 2022Buy+37,500$4.00$150.00K62,500
Gary S. Jacob
Chief Executive Officer, Director
May 19, 2022Buy+12,500$4.00$50.00K12,500
Gabriele M. Cerrone
Non-Executive Chairman, Director, 10% owner
May 17, 2022Buy+1,625,000$0.06$97.50K544,806,215
Gabriele M. Cerrone
Non-Executive Chairman, Director, 10% owner
May 17, 2022Buy+25,000$3.87$96.75K25,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.15%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-40.5%
From 0M shares
Short volume, 20 days
28.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of OKYO Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,267 shares on Sep 22, 2026 over the last 90 days.

See a number that looks wrong?